ArticlePituitary2008
Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.
Article in Pituitary, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- Pooled it
- [Matrix metalloproteinases in pituitary adenoma invasiveness].Problemy endokrinologii · 2026Review
- Radiolabeling molecular biomarkers of invasive pituitary adenomas: a narrative review.Pituitary · 2025Review
- Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications.Journal of clinical & translational endocrinology · 2025Review
- Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.BMC endocrine disorders · 2025Article
- Association between transcription factors expression and growth patterns of nonfunctioning pituitary adenomas.Scientific reports · 2025Article
- Expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and their relationship with cavernous sinus invasion.Endocrine oncology (Bristol, England) · 2025Article
- Clinical and therapeutic implications of cavernous sinus invasion in pituitary adenomas.Endocrine · 2024Review
- Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- Tumour microenvironment and pituitary tumour behaviour.Journal of endocrinological investigation · 2023Review
- Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma.Brain sciences · 2023Article
- Does the functional polymorphism-1562C/T of MMP-9 gene influence brain disorders?Frontiers in cellular neuroscience · 2023Review
- Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.The EPMA journal · 2021Review
- Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors.Biomedicines · 2020Review
- Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas.Journal of molecular neuroscience : MN · 2019Article
- LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p.OncoTargets and therapy · 2019Article
- Molecular Network Basis of Invasive Pituitary Adenoma: A Review.Frontiers in endocrinology · 2019Review
- Role of matrix Metalloproteinases in pituitary adenoma invasion.Chinese neurosurgical journal · 2018Review
- Does MMP-9 Gene Polymorphism Play a Role in Pituitary Adenoma Development?Disease markers · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectWe analyzed MMP-9 expression using mRNA and protein level determinations and explored the possibility that matrix metalloproteinase-9 (MMP-9) is a potential biological marker of pituitary adenoma invasiveness and whether MMP-9 could be used to discriminate the extent of invasiveness among different hormonal subtypes, tumor sizes, growth characteristics, and primary versus recurrent tumors. MATERIALS AND
methods73 pituitary tumor specimens were snap frozen in liquid nitrogen immediately after surgical resection. RNA and protein were extracted. MMP-9 mRNA transcripts were analyzed by quantitative RT-PCR. MMP-9 protein activity was analyzed by gelatin zymography and validated by western blot analysis. Immunohistochemistry was performed to identify the presence and localization of MMP-9 in pituitary adenomas. Statistical differences between results were determined using Student's t-test or one way ANOVA.
resultsComparing different hormonal subtypes of noninvasive and invasive pituitary tumors, MMP-9 mRNA expression was significantly increased in the majority of invasive adenomas. Considering the protein levels, our data also showed a significant increase in MMP-9 activity in the majority of invasive adenomas and these differences were confirmed by western blot analysis and immunohistochemistry. In addition, consistent differences in MMP-9 expression levels were found according to tumor subtype, tumor size, tumor extension and primary versus redo-surgery.
conclusionsMMP-9 expression can consistently distinguish invasive pituitary tumors from noninvasive pituitary tumors and would reflect the extent of invasiveness in pituitary tumors according to tumor subtype, size, tumor extension, primary and redo surgery, even at early stages of invasiveness. MMP-9 may be considered a potential biomarker to determine and predict the invasive nature of pituitary tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.